Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07509151 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Study acronym: SOUNDTRACK-C1
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 20 words Secondary endpoints: details revised at 7 of 12 entries · Study description revised · Site details revised at 6 of 44 sites Show 3 more changesShow less
    • Secondary endpoints: details revised at 7 of 12 entries
    • Study description revised
    • Site details revised at 6 of 44 sites
  2. Trial sites expanded: 30 → 44 locationsv5
  3. Site details revised at 6 of 30 sitesv4
  4. Site details revised at 7 of 30 sitesv3
  5. Recruitment opened Primary completion moved earlier from Nov 29, 2032 to Aug 29, 2031 · Trial sites expanded: 13 → 30 locations · Completion moved earlier from Aug 29, 2033 to Apr 5, 2032 · 1 morev2 Show 4 more changesShow less
    • Primary completion moved earlier from Nov 29, 2032 to Aug 29, 2031
    • Trial sites expanded: 13 → 30 locations
    • Completion moved earlier from Aug 29, 2033 to Apr 5, 2032
    • Start date changed from estimate of Apr 8, 2026 to May 5, 2026
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) with unmutated IGHV (uIGHV).
Trial Details
NCT Number NCT07509151
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
Enrollment 420 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov